JP2004536843A - ピオグリタゾンおよびビグアナイドを含むコア製剤 - Google Patents

ピオグリタゾンおよびビグアナイドを含むコア製剤 Download PDF

Info

Publication number
JP2004536843A
JP2004536843A JP2003511802A JP2003511802A JP2004536843A JP 2004536843 A JP2004536843 A JP 2004536843A JP 2003511802 A JP2003511802 A JP 2003511802A JP 2003511802 A JP2003511802 A JP 2003511802A JP 2004536843 A JP2004536843 A JP 2004536843A
Authority
JP
Japan
Prior art keywords
core
glucopyranosyl
metformin
alpha
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003511802A
Other languages
English (en)
Japanese (ja)
Inventor
アジェイ，アクウィート，エル．
ヤピン ジュー，
キューティ，アンソニー，ジェイ．
Original Assignee
エアロファーム テクノロジー インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エアロファーム テクノロジー インコーポレイテッド filed Critical エアロファーム テクノロジー インコーポレイテッド
Publication of JP2004536843A publication Critical patent/JP2004536843A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2003511802A 2001-07-10 2001-07-10 ピオグリタゾンおよびビグアナイドを含むコア製剤 Pending JP2004536843A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2001/021615 WO2003005995A1 (fr) 2001-07-10 2001-07-10 Preparation de noyau comprenant un hydrochlorure de pioglitazone et un biguanide

Publications (1)

Publication Number Publication Date
JP2004536843A true JP2004536843A (ja) 2004-12-09

Family

ID=21742689

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003511802A Pending JP2004536843A (ja) 2001-07-10 2001-07-10 ピオグリタゾンおよびビグアナイドを含むコア製剤

Country Status (6)

Country Link
EP (1) EP1429747A4 (fr)
JP (1) JP2004536843A (fr)
AU (1) AU2001273289B2 (fr)
CA (1) CA2453775A1 (fr)
MX (1) MXPA04000180A (fr)
WO (1) WO2003005995A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1429732A4 (fr) * 2001-07-10 2005-01-26 Kos Life Sciences Inc Formulation de noyau
EP1552832A1 (fr) * 2002-07-11 2005-07-13 Takeda Pharmaceutical Company Limited Procede de production d'une preparation recouverte
EP1588708A4 (fr) 2003-01-29 2006-03-01 Takeda Pharmaceutical Procede pour realiser une preparation enrobee
GB0316940D0 (en) * 2003-07-19 2003-08-27 Ward Warren Treatment of skin and other medical conditions
CA2532344A1 (fr) 2003-07-19 2005-02-17 Warren Ward Compositions comprenant des composants enrobes d'une couche permeable aux gaz mais impermeables aux liquides, leur utilisation pour le traitement d'affections de la peau et de la glande exocrine
WO2005021542A2 (fr) * 2003-08-28 2005-03-10 Ranbaxy Laboratories Limited Procede pour la preparation de pioglitazone
US20060153889A1 (en) * 2005-01-10 2006-07-13 Friel Francis M Discontinuous surface coating for particles
MXPA05014092A (es) * 2005-12-20 2007-06-20 Leopoldo De Jesus Espinosa Abdala Composiciones farmaceuticas que comprenden sustancias derivadas de la tiazolidinedionas combinadas con una biguanida para su uso en diabetes mellitus tipo 2.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US6416774B1 (en) * 1996-05-09 2002-07-09 The Trustees Of The University Of Pennsyvania Hollow bone mineral-like calcium phosphate particles
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
GB9715295D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
US6358531B1 (en) * 1999-02-01 2002-03-19 The Curators Of The University Of Missouri Method for preparing porous shells or gels from glass particles
US6451342B2 (en) * 2000-05-01 2002-09-17 Aeropharm Technology Incorporated Core formulation comprised of troglitazone and a biguanide
US6780432B1 (en) * 2000-05-01 2004-08-24 Aeropharm Technology, Inc. Core formulation
EP1429732A4 (fr) * 2001-07-10 2005-01-26 Kos Life Sciences Inc Formulation de noyau

Also Published As

Publication number Publication date
MXPA04000180A (es) 2004-11-22
EP1429747A1 (fr) 2004-06-23
CA2453775A1 (fr) 2003-01-23
AU2001273289B2 (en) 2004-10-07
WO2003005995A1 (fr) 2003-01-23
EP1429747A4 (fr) 2005-01-05

Similar Documents

Publication Publication Date Title
US6524621B2 (en) Core formulation
US6451342B2 (en) Core formulation comprised of troglitazone and a biguanide
US6403121B1 (en) Core formulation
US6780432B1 (en) Core formulation
US6296874B1 (en) Core formulation comprising troglitazone and abiguanide
RU2276604C2 (ru) Антидиабетический препарат и способ лечения диабета
BRPI0616694B1 (pt) Processo para preparar comprimido farmacêutico com 80 e 96% em peso com base no peso seco de vildagliptina e metformina ou seus sais farmaceuticamente aceitáveis
OA11677A (en) Pharmaceutical composition for modified release ofan insulin sensitiser and another antidiabetic agent.
FR2825023A1 (fr) Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
JP2005516919A (ja) 抗糖尿病製剤および方法
MXPA02004282A (es) Metodo para tratar la diabetes.
US6461639B2 (en) Core formulation
JP2004536843A (ja) ピオグリタゾンおよびビグアナイドを含むコア製剤
WO2007007757A1 (fr) Composition pharmaceutique contenant un agoniste de ppar$g(g)
AU2001273289A1 (en) Core formulation comprising pioglitazone hydrochloride and a biguanide
JP2004536841A (ja) コア製剤
EP1278513B1 (fr) Formulation de noyaux
AU2001273310A1 (en) A core formulation
AU2001257456A1 (en) A core formulation
JP2004536842A (ja) トログリタゾンおよびビグアナイドを含むコア製剤
AU2001273290A1 (en) Core formulation comprising troglitazone and a biguanide
TWI248815B (en) The controlled release formulation of metformin HCl
UA73927C2 (en) Pharmaceutical composition of thiasolidindion and metformin providing for pulsating or delayed release for one of ingredients